ZYDUSLIFE Stock Overview
Engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 0/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 4/6 |
Zydus Lifesciences Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹1,111.55 |
52 Week High | ₹1,324.30 |
52 Week Low | ₹567.75 |
Beta | 0.46 |
11 Month Change | -11.07% |
3 Month Change | 10.76% |
1 Year Change | 79.14% |
33 Year Change | 99.60% |
5 Year Change | 370.40% |
Change since IPO | 12,710.92% |
Recent News & Updates
Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market
Aug 30Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Aug 14Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment
Aug 03Recent updates
Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market
Aug 30Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Aug 14Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment
Aug 03Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
Jul 19Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 05Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
Jun 20Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Jun 10Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year
May 25Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?
Mar 18Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%
Feb 28Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report
Feb 12Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Dec 27Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors
Dec 06With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case
Aug 23Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
Jul 17We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Jul 15Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's
Jun 24Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00
Jun 10Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
May 21Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly
Feb 15We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Nov 13Shareholder Returns
ZYDUSLIFE | IN Pharmaceuticals | IN Market | |
---|---|---|---|
7D | 0.3% | 2.4% | 1.0% |
1Y | 79.1% | 60.9% | 44.8% |
Return vs Industry: ZYDUSLIFE exceeded the Indian Pharmaceuticals industry which returned 60.9% over the past year.
Return vs Market: ZYDUSLIFE exceeded the Indian Market which returned 44.8% over the past year.
Price Volatility
ZYDUSLIFE volatility | |
---|---|
ZYDUSLIFE Average Weekly Movement | 4.6% |
Pharmaceuticals Industry Average Movement | 6.3% |
Market Average Movement | 6.8% |
10% most volatile stocks in IN Market | 9.8% |
10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: ZYDUSLIFE has not had significant price volatility in the past 3 months.
Volatility Over Time: ZYDUSLIFE's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1952 | 26,921 | Sharvil Patel | zyduslife.com |
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases.
Zydus Lifesciences Limited Fundamentals Summary
ZYDUSLIFE fundamental statistics | |
---|---|
Market cap | ₹1.12t |
Earnings (TTM) | ₹41.69b |
Revenue (TTM) | ₹206.15b |
26.8x
P/E Ratio5.4x
P/S RatioIs ZYDUSLIFE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ZYDUSLIFE income statement (TTM) | |
---|---|
Revenue | ₹206.15b |
Cost of Revenue | ₹63.05b |
Gross Profit | ₹143.10b |
Other Expenses | ₹101.41b |
Earnings | ₹41.69b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 41.43 |
Gross Margin | 69.41% |
Net Profit Margin | 20.22% |
Debt/Equity Ratio | 3.7% |
How did ZYDUSLIFE perform over the long term?
See historical performance and comparison